BioSim™ anti-Adalimumab II (Human) ELISA Kit

Alternate Name :

Tag Line :

A Sandwich ELISA kit for the qualitative measurement of antibodies to Adalimumab in human serum or plasma samples

Storage Conditions: 4ºC

Shelf life: 12 months

Summary :

Detection Method: Absorbance (450 nm)

Features & Benefits:

For in vitro qualitative determination of antibodies to Adalimumab in human serum and plasma samples,Assay Precision: Intra-Assay and Inter-Assay CV < 30%,Cross Reactivity: Except for Adalimumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins

Description:

Adalimumab is a fully human monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α). TNF is a proinflammatory cytokine that plays an important role in the immune and inflammatory response. Binding of the antibody to TNF-α prevents its interaction with p55 and p75 cell surface TNF receptors. Additionally, it lyses cell surface localized TNF in the presence of complement. The antibody has been approved to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioSim™ anti-Adalimumab ELISA kit has been specifically developed to qualitatively determine antibodies to Adalimumab in human serum and plasma samples. The ELISA kit is based on the sandwich principle. Controls and samples (serum and plasma) are incubated in the microtiter plate coated with the drug Adalimumab. After incubation, the wells are washed and the enzymatic activity is detected by the addition of chromogen-substrate. The enzyme-substrate reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies specific for Adalimumab present in the samples and controls. The qualitative test results can be evaluated using cut-off value.